388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study

平台已收录预计检索 <10 秒

查看已审核书目、规范引用与获取指引。下载与积分规则登录后查看。

文献信息

题目: 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
作者: Y-L. Wu, J. Zhao, J. Hu, J. Wu, Y. Xu, Z. Yang, Z. Liu, L. Jiang, J. Chen, Y. Yu, M. Huang, X. Dong, L. Liu, W. Feng, L. Wu, S. Cang, J. Sun, Q. Xie, H-J. Chen
发表年份: 2022
期刊 / 来源: Annals of Oncology
出版社: Elsevier
DOI: 10.1016/j.annonc.2022.10.425
文献类型: 学术文献
平台记录更新: 2026-09-17 22:13:50

本页由 Scihuhuan.com 学术互换提供文献检索、引用与获取指引；论文版权和出版身份归原出版方。